To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

PHASE2CompletedINTERVENTIONAL
Enrollment

370

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Partial Epilepsies
Interventions
DRUG

lacosamide

50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial

Trial Locations (59)

Unknown

Birmingham

Huntsville

Phoenix

Tucson

Little Rock

Los Angeles

Englewood

Gainesville

Hollywood

Miami

Ponte Vedra Beach

Chicago

Springfield

Indianapolis

Iowa City

Wichita

Crestview Hills

Lexington

Baltimore

Frederick

Boston

Ann Arbor

Detroit

Saint Paul

Chesterfield

St Louis

Somerset

New York

Durham

Cincinnati

Cleveland

Columbus

Hershey

Philadelphia

Nashville

Dallas

Irving

Lubbock

Wichita Falls

Bennington

Charlottesville

Marshfield

Milwaukee

Bonn

Erlangen

Kehl Kork

Schwalmstedt-Treysa

Budapest

Zalaegerszeg

Kaunas

Vilnius

Poznan

Gothenburg

Stockholm

Bern/Biel

Zurich

Bucks/London

Glasgow

Liverpool

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY